Drug Trial Radar · NCT00000136
Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
234
Actual
Start
Mar 1990
Primary completion
Oct 1991
Study completion Oct 1991
Sponsor
- Lead sponsor
- Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Eye Institute (NEI); Johns Hopkins University; University of Wisconsin, Madison; Baylor College of Medicine; Louisiana State University Health Sciences Center in New Orleans; New York Presbyterian Hospital; Icahn School of Medicine at Mount Sinai; NYU Langone Health; Northwestern University; University of California, Los Angeles; University of California, San Diego; University of California, San Francisco; University of Miami; University of Massachusetts, Worcester; Memorial Sloan Kettering Cancer Center
- First posted
- Sep 24, 1999
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the relative safety and efficacy of ganciclovir and foscarnet as initial treatment of patients with cytomegalovirus (CMV) retinitis.
Conditions
- HIV Infections
- Cytomegalovirus Retinitis
Interventions
FoscarnetDrug
60 mg/kg every 8 hours, 90 mg/kg/day
GanciclovirDrug
5 mg/kg every 12 hours, 5 mg/kg every 24 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.